Evelo Biosciences, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q3 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Evelo Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q3 2023.
  • Evelo Biosciences, Inc. Debt-to-equity for the quarter ending September 30, 2023 was -241 %, a 129% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2023 -241 -1.08K -129% Sep 30, 2023
Q2 2023 -409 -928 -179% Jun 30, 2023
Q1 2023 2.32K +1.95K +528% Mar 31, 2023
Q4 2022 1.29K +1.12K +694% Dec 31, 2022
Q3 2022 836 +699 +512% Sep 30, 2022
Q2 2022 519 +405 +356% Jun 30, 2022
Q1 2022 369 +275 +291% Mar 31, 2022
Q4 2021 162 +55 +51.3% Dec 31, 2021
Q3 2021 137 +57.4 +72.5% Sep 30, 2021
Q2 2021 114 +53.7 +89.4% Jun 30, 2021
Q1 2021 94.3 +47.5 +101% Mar 31, 2021
Q4 2020 107 +76.5 +249% Dec 31, 2020
Q3 2020 79.2 +55.7 +237% Sep 30, 2020
Q2 2020 60.1 +41 +214% Jun 30, 2020
Q1 2020 46.8 +30.4 +185% Mar 31, 2020
Q4 2019 30.7 +7 +29.5% Dec 31, 2019
Q3 2019 23.5 -19.2 -44.9% Sep 30, 2019
Q2 2019 19.1 Jun 30, 2019
Q1 2019 16.5 Mar 31, 2019
Q4 2018 23.7 Dec 31, 2018
Q3 2018 42.7 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.